The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
ARQ 197 in patients with previously-treated malignant mesothelioma (MM): A phase II trial from the University of Chicago Phase II Consortium.
 
Steven Brad Maron
No Relationships to Disclose
 
Theodore Karrison
No Relationships to Disclose
 
Rajani Kanteti
No Relationships to Disclose
 
Krishna A. Rao
No Relationships to Disclose
 
David R. Gandara
Honoraria - Array BioPharma; AstraZeneca; Celgene; Lilly; Novartis; Synta
Consulting or Advisory Role - Amgen; AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Genentech; GlaxoSmithKline; Lilly; Merck; Novartis; Pfizer; Response Genetics; Sanofi; Synta
Research Funding - Abbott Laboratories (Inst); Bristol-Myers Squibb (Inst); Genentech (Inst); ImClone Systems (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Biomarin; Boehringer Ingelheim; Dava Oncology; Pfizer
 
Marianna Koczywas
No Relationships to Disclose
 
Ravi Salgia
No Relationships to Disclose
 
Hedy Lee Kindler
Consulting or Advisory Role - AstraZeneca/MedImmune; Celgene; Genentech/Roche; Gilead Sciences; GlaxoSmithKline; Seagen; Verastem
Research Funding - AB Science (Inst); Aduro Biotech (Inst); Astellas Pharma (Inst); AstraZeneca/MedImmune (Inst); Celgene (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Merck (Inst); Verastem (Inst)